Furthermore, in scRNA sequencing of melanoma, exhausted/effector CD8+ TILs showed significantly lower ELOVL1 expression in responders than in nonresponders and resistant patients (Fig. 2k), suggesting that ELOVL1low TILs are more effective in synergizing with anti-PD-1 treatment than ELOVL1high TILs. The gene discussed is CD8A; the disease is melanoma.